New combo attack on rare eye cancer shows promise in early trial
NCT ID NCT06627244
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether combining a targeted immunotherapy (tebentafusp) with a liver-directed radiation treatment (Y-90 radioembolization) can help control metastatic uveal melanoma that has spread to the liver. About 30 adults whose cancer is mainly in the liver and who have a specific genetic marker (HLA-A*02:01) will receive both treatments. The goal is to see how long the cancer stays under control and what side effects occur.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Miami
RECRUITINGMiami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a drug duo tame a rare eye cancer that has spread?
- Can a new drug shrink Hard-to-Treat eye cancer?
- Double immunotherapy plus liver blockade targets eye cancer that spreads
- First-in-Class cancer drug targets Hard-to-Treat tumors
- Engineered immune cells take on Hard-to-Treat melanoma
- Immune cell therapy shows promise against rare eye cancer